دورية أكاديمية
أعرض في EDS

Effect of probenecid on blood levels and renal elimination of furosemide and endogenous compounds in rats: Discovery of putative organic anion transporter biomarkers.

التفاصيل البيبلوغرافية
العنوان: Effect of probenecid on blood levels and renal elimination of furosemide and endogenous compounds in rats: Discovery of putative organic anion transporter biomarkers.
المؤلفون: Thakur A; College of Pharmacy and Pharmaceutical Sciences, Washington State University, Spokane, WA 99202, USA., Saradhi Mettu V; College of Pharmacy and Pharmaceutical Sciences, Washington State University, Spokane, WA 99202, USA., Singh DK; College of Pharmacy and Pharmaceutical Sciences, Washington State University, Spokane, WA 99202, USA., Prasad B; College of Pharmacy and Pharmaceutical Sciences, Washington State University, Spokane, WA 99202, USA. Electronic address: bhagwat.prasad@wsu.edu.
المصدر: Biochemical pharmacology [Biochem Pharmacol] 2023 Dec; Vol. 218, pp. 115867. Date of Electronic Publication: 2023 Oct 20.
نوع المنشور: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: Elsevier Science Country of Publication: England NLM ID: 0101032 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-2968 (Electronic) Linking ISSN: 00062952 NLM ISO Abbreviation: Biochem Pharmacol Subsets: MEDLINE
أسماء مطبوعة: Publication: Oxford : Elsevier Science
Original Publication: Oxford, New York [etc.] Paragamon Press.
مواضيع طبية MeSH: Organic Anion Transporters*/metabolism, Rats ; Animals ; Probenecid/pharmacology ; Probenecid/metabolism ; Organic Anion Transporters, Sodium-Independent/metabolism ; Renal Elimination ; Furosemide/pharmacology ; Furosemide/metabolism ; Organic Anion Transport Protein 1/metabolism ; Kynurenic Acid/metabolism ; Kynurenic Acid/pharmacology ; Pyridoxic Acid/metabolism ; Pyridoxic Acid/pharmacology ; Drug Interactions ; Biomarkers/metabolism ; Kidney/metabolism
مستخلص: Transporter-mediated drug-drug interactions (DDIs) are assessed using probe drugs and in vitro and in vivo models during drug development. The utility of endogenous metabolites as transporter biomarkers is emerging for prediction of DDIs during early phases of clinical trials. Endogenous metabolites such as pyridoxic acid and kynurenic acid have shown potential to predict DDIs mediated by organic anion transporters (OAT1 and OAT3). However, these metabolites have not been assessed in rats as potential transporter biomarkers. We carried out a rat pharmacokinetic DDI study using probenecid and furosemide as OAT inhibitor and substrate, respectively. Probenecid administration led to a 3.8-fold increase in the blood concentrations and a 3-fold decrease in renal clearance of furosemide. High inter-individual and intra-day variability in pyridoxic acid and kynurenic acid, and no or moderate effect of probenecid administration on these metabolites suggest their limited utility for prediction of Oat-mediated DDI in rats. Therefore, rat blood and urine samples were further analysed using untargeted metabolomics. Twenty-one m/z features (out of >8000 detected features) were identified as putative biomarkers of rat Oat1 and Oat3 using a robust biomarker qualification approach. These m/z features belong to metabolic pathways such as fatty acid analogues, peptides, prostaglandin analogues, bile acid derivatives, flavonoids, phytoconstituents, and steroids, and can be used as a panel to decrease variability caused by processes other than Oats. When validated, these putative biomarkers will be useful in predicting DDIs caused by Oats in rats.
Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
(Copyright © 2023 Elsevier Inc. All rights reserved.)
References: Clin Pharmacokinet. 1999 Feb;36(2):127-43. (PMID: 10092959)
Drug Metab Dispos. 2019 Aug;47(8):802-808. (PMID: 31123036)
Clin Pharmacol Ther. 2023 May;113(5):986-1002. (PMID: 35869864)
Physiol Genomics. 2008 Apr 22;33(2):180-92. (PMID: 18270321)
Drug Metab Dispos. 2013 Oct;41(10):1825-34. (PMID: 23920220)
J Pharm Anal. 2023 Oct;13(10):1205-1220. (PMID: 38024860)
Pharmacy (Basel). 2018 May 14;6(2):. (PMID: 29757930)
J Clin Invest. 1951 Jul;30(7):697-700. (PMID: 14850548)
Clin Pharmacol Ther. 2018 Nov;104(5):836-864. (PMID: 30347454)
Pharmacol Ther. 2012 Oct;136(1):106-30. (PMID: 22841915)
Pharmaceutics. 2022 Oct 27;14(11):. (PMID: 36365126)
Br J Clin Pharmacol. 1979 Nov;8(5):491-5. (PMID: 508557)
Clin Pharmacol Ther. 2019 Nov;106(5):1083-1092. (PMID: 31127606)
Sci Rep. 2017 Jul 10;7(1):4939. (PMID: 28694431)
Drug Metab Dispos. 2013 Jun;41(6):1174-8. (PMID: 23569176)
J Clin Invest. 1985 Aug;76(2):752-6. (PMID: 4031070)
Pharm Res. 2017 Aug;34(8):1601-1614. (PMID: 28550384)
Am J Clin Nutr. 1979 May;32(5):1024-32. (PMID: 433819)
Drug Metab Dispos. 2016 Dec;44(12):1925-1933. (PMID: 27638508)
Physiol Rev. 2015 Jan;95(1):83-123. (PMID: 25540139)
Clin Pharmacol Ther. 1981 Nov;30(5):587-93. (PMID: 7297018)
Clin Pharmacokinet. 2021 Sep;60(9):1187-1199. (PMID: 33840062)
Gynecol Obstet Invest. 2013;76(3):163-70. (PMID: 24008262)
Drug Metab Dispos. 2014 Apr;42(4):685-94. (PMID: 24487120)
J Pediatr. 1983 Sep;103(3):481-5. (PMID: 6886918)
Am J Clin Nutr. 1995 Nov;62(5):979-83. (PMID: 7572745)
Metabolites. 2018 May 10;8(2):. (PMID: 29748461)
Eur J Pharmacol. 2006 Jul 1;540(1-3):168-74. (PMID: 16756973)
Eur J Clin Pharmacol. 1977 Aug 17;12(1):15-22. (PMID: 902673)
AAPS J. 2019 Jul 11;21(5):88. (PMID: 31297641)
Eur J Clin Pharmacol. 1984;26(2):197-207. (PMID: 6723758)
Clin Pharmacol Ther. 1974 Feb;15(2):178-86. (PMID: 4812154)
Eur J Pharm Sci. 2014 Aug 1;59:94-103. (PMID: 24747579)
Br J Clin Pharmacol. 1995 Jun;39(6):692-5. (PMID: 7654491)
J Clin Pharmacol. 2016 Jul;56 Suppl 7:S110-21. (PMID: 27385169)
JCI Insight. 2023 Jan 24;8(2):. (PMID: 36692015)
J Clin Pharmacol. 1990 Jan;30(1):50-6. (PMID: 2303581)
Clin Pharmacokinet. 2003;42(14):1193-211. (PMID: 14606929)
J Biol Chem. 2006 Feb 24;281(8):5072-83. (PMID: 16354673)
J Pharmacol Exp Ther. 2019 Jan;368(1):136-145. (PMID: 30361237)
J Pharm Sci. 1980 May;69(5):571-5. (PMID: 7381747)
Am J Clin Nutr. 2002 Jan;75(1):57-64. (PMID: 11756060)
Clin Pharmacol Ther. 2022 Sep;112(3):653-664. (PMID: 35490380)
Eur J Clin Pharmacol. 1981;20(1):27-33. (PMID: 7308269)
J Am Soc Nephrol. 2008 Sep;19(9):1732-40. (PMID: 18508962)
Drug Metab Dispos. 2018 Feb;46(2):178-188. (PMID: 29162614)
Drug Metab Dispos. 2021 Dec;49(12):1063-1069. (PMID: 34599018)
J Proteome Res. 2011 Jun 3;10(6):2842-51. (PMID: 21476605)
Clin Pharmacol Ther. 1968 May-Jun;9(3):345-9. (PMID: 5649987)
Clin Pharmacol Ther. 1995 Nov;58(5):532-41. (PMID: 7586947)
Clin J Am Soc Nephrol. 2015 Nov 6;10(11):2039-49. (PMID: 26490509)
Pflugers Arch. 2014 May;466(5):925-35. (PMID: 24057348)
Antimicrob Agents Chemother. 1998 Feb;42(2):456-8. (PMID: 9527807)
Biopharm Drug Dispos. 2002 Oct;23(7):283-91. (PMID: 12355579)
معلومات مُعتمدة: R01 HD081299 United States HD NICHD NIH HHS
فهرسة مساهمة: Keywords: Biomarker; Furosemide; Metabolomics; Oat1; Oat3; Probenecid
المشرفين على المادة: 0 (Organic Anion Transporters)
PO572Z7917 (Probenecid)
0 (Organic Anion Transporters, Sodium-Independent)
7LXU5N7ZO5 (Furosemide)
0 (Organic Anion Transport Protein 1)
H030S2S85J (Kynurenic Acid)
5K18793O8D (Pyridoxic Acid)
0 (Biomarkers)
تواريخ الأحداث: Date Created: 20231022 Date Completed: 20231204 Latest Revision: 20240229
رمز التحديث: 20240229
مُعرف محوري في PubMed: PMC10900896
DOI: 10.1016/j.bcp.2023.115867
PMID: 37866801
قاعدة البيانات: MEDLINE
الوصف
تدمد:1873-2968
DOI:10.1016/j.bcp.2023.115867